Patients with a history of bleeding diathesis are ineligible
History of bleeding diathesis or clinically significant bleeding within  days prior to randomization.
History of hemolytic anemia or bleeding diathesis
PHASE II: History of bleeding diathesis; patients receiving anti-coagulation must be able safely interrupt treatment for tumor biopsy
Known hemorrhagic diathesis or active bleeding disorder
Subjects may not have a history of bleeding diathesis or abnormal sensitivity to ionizing radiation
Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumarin)
Vascular abnormalities or bleeding diathesis that indicates hepatic artery catheterization is contraindicated
Recent or active bleeding diathesis or arterial vascular event within  weeks
History of hemolytic anemia or bleeding diathesis or positive direct antiglobulin test.
Requires therapeutic anticoagulation or has known active bleeding diathesis
Contraindication for ibrutinib use because of a bleeding diathesis.
Normal coagulation profile and no history of substantial non-iatrogenic bleeding diathesis
Inability to tolerate aspirin, or other forms of anticoagulation, due to bleeding diathesis
History of bleeding diathesis
Patients must have normal coagulation profile and no history of substantial non-iatrogenic bleeding diathesis.
Any evidence of bleeding diathesis (patients on therapeutic warfarin or heparin will be excluded)
Known history of bleeding diathesis
Evidence or history of bleeding diathesis
Patient on anticoagulation or with bleeding diathesis due to risk of hematomas at injection site
Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular injections of fulvestrant or goserelin (if applicable)
For patients undergoing serial tumor biopsies, known bleeding diathesis or history of abnormal bleeding or require anti-coagulation therapy which cannot be interrupted for biopsy
PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery
Evidence or history of bleeding diathesis
Personal or family history of bleeding diathesis and a coagulation profile that would preclude patient from undergoing a neurosurgical procedure
History of bleeding disorder or diathesis
Presence of bleeding diathesis
Evidence of uncontrollable bleeding diathesis
Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery
Bleeding diathesis, not correctable by usual forms of therapy
Bleeding diathesis, not correctable by usual forms of therapy
Haemorrhagic diathesis (i.e. haemophilia)
Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular injections of fulvestrant or goserelin (if applicable).
Subjects with known bleeding diathesis will be excluded from the study.
Patients with history of bleeding diathesis are ineligible
Subjects with history of bleeding diathesis
Known hemorrhagic diathesis or active bleeding disorder
History of bleeding diathesis.
Known history of a bleeding diathesis.
History of congenital bleeding diathesis
Evidence of bleeding diathesis or clinically significant bleeding, within  days of CD or history of hemoptysis of > . mL/ teaspoon within  months of CD
Patients with history of bleeding diathesis
History of hemolytic anemia or bleeding diathesis
In the opinion of the investigator, bleeding diathesis or anticoagulation therapy that would preclude intramuscular injections
Evidence of history of bleeding diathesis.
Patients with evidence or history of any bleeding diathesis, irrespective of severity
Bleeding diathesis or use of warfarin or other vitamin K antagonist
History of bleeding diathesis
History of bleeding diathesis or extensive bleeding requiring blood transfusion within  days of enrollment
Contraindications to seed placement, including uncontrollable bleeding diathesis
Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low-dose warfarin and aspirin or equivalent, as long as the INR =< .)
Known bleeding diathesis
Patients taking anticoagulants or with a history of a bleeding diathesis
Have evidence or history of any bleeding diathesis (including mild hemophilia), irrespective of severity.
Evidence of a bleeding diathesis that cannot be corrected with standard therapy or factor replacement
History of bleeding diathesis or known qualitative platelet defect (including von Willebrand disease)
Known bleeding diathesis or hemophilia
History of bleeding diathesis, known factor X deficiency (level < %), or requirement for therapeutic anticoagulation with warfarin
Known bleeding diathesis.
For patients undergoing serial tumor biopsies, known bleeding diathesis or history of abnormal bleeding or require anti-coagulation therapy.
No history of bleeding diathesis.
History of bleeding diathesis
History of bleeding diathesis
Known bleeding diathesis
Patients with evidence of a bleeding diathesis that cannot be corrected with standard therapy or factor replacement
for intratumoral cohort, bleeding diathesis or use of anticoagulants/antiplatelet agents that cannot be stopped
No known bleeding diathesis
Known bleeding or thrombotic diathesis
Bleeding diathesis or inability to hold anticoagulation for surgery
Has known bleeding diathesis that would be a safety risk;
Non-correctable bleeding diathesis
Familial bleeding diathesis
Known bleeding diathesis
History of a bleeding diathesis or current anticoagulant therapy
Patients with or with a history of uncontrolled bleeding diathesis
Patients with an active bleeding diathesis or on oral anti-vitamin K medication (except low-dose warfarin used for catheter-related thrombosis prophylaxis)
No history of bleeding diathesis
Known bleeding diathesis or history of abnormal bleeding, or any other known coagulation abnormalities that would contraindicate the tumor biopsy procedure.
Known bleeding diathesis or history of abnormal bleeding, or any other known coagulation abnormalities that would contraindicate the tumor biopsy procedure.
